Postoperative radiation therapy for grade II and III intracranial ependymoma

David B. Mansur, Arie Perry, Veena Rajaram, Jeff M. Michalski, T. S. Park, Jeffrey R. Leonard, Lori Luchtman-Jones, Keith M. Rich, Perry W. Grigsby, Mary Ann Lockett, Sasha H. Wahab, Joseph R. Simpson

Research output: Contribution to journalArticlepeer-review

74 Scopus citations


To retrospectively determine the long-term outcome of intracranial ependymoma patients treated with surgery and postoperative radiation therapy. Sixty patients were treated at our institution between 1964 and 2000. Forty patients had World Health Organization Grade II ependymoma, and 20 patients had Grade III ependymoma. The median patient age was 10.7 years. The majority of patients were male (55%), had infratentorial tumors (80%), and had subtotal resections (72%). Postoperative radiation therapy was delivered to all patients to a median total dose of 50.4 Gy. Craniospinal radiation therapy was used in the earlier era in only 12 patients (20%). The median follow-up of surviving patients was 12.5 years. The 5-year and 10-year disease-free survival rates for all patients were 58.4% and 49.5%, respectively. The 5-year and 10-year overall survival rates for all patients were 71.2% and 55.0%, respectively. Supratentorial tumor location was independently associated with a worse disease-free survival. Subtotal resection and supratentorial location predicted a worse overall survival, but this failed to reach statistical significance. No statistically significant effect on prognosis was observed with tumor grade, patient age, or radiation dose or volume. Our long-term follow-up indicates that half of ependymoma patients will have disease recurrences, indicating the need for more effective treatments.

Original languageEnglish
Pages (from-to)387-391
Number of pages5
JournalInternational Journal of Radiation Oncology Biology Physics
Issue number2
StatePublished - Feb 1 2005


  • Ependymoma
  • Radiation therapy


Dive into the research topics of 'Postoperative radiation therapy for grade II and III intracranial ependymoma'. Together they form a unique fingerprint.

Cite this